APRINOIA THERAPEUTICS LIMITED

APRINOIA Therapeutics Limited is a cutting‑edge biotechnology company dedicated to giving patients with neurodegenerative disorders a clearer picture of their condition and a brighter tomorrow. By harnessing precision‑medicine approaches, APRINOIA targets the protein aggregates—such as tau and α‑synuclein—that drive the pathology of illnesses like Alzheimer’s and Parkinson’s disease, aiming to protect brain health and preserve dignity.

The company’s portfolio spans both diagnostic and therapeutic programmes. Its active diagnostic platforms are designed to detect disease at the earliest stages and to monitor progression in response to novel treatments. Complementing this, APRINOIA’s robust pipeline of small‑ and large‑molecule candidates seeks to intervene directly in the underlying protein pathways, with the ultimate goal of slowing disease progression and maintaining patients’ cognitive function before hope is lost.

Through these next‑generation solutions, APRINOIA serves patients, clinicians and researchers worldwide, offering innovative tools that bring new clarity to the fight against neurodegeneration.